The Groundbreaking KidneyGenAfrica Study Led by Wits University

A team of researchers from the University of the Witwatersrand (Wits) in Johannesburg has spearheaded what is described as the largest genomic study of kidney function ever conducted in African populations. Published in Nature Communications on February 10, 2026, with a major press announcement on March 31, 2026, the study analyzed data from approximately 110,000 individuals of African ancestry, including around 26,000 from continental Africa across Eastern, Western, and Southern regions. This massive effort, coordinated through the KidneyGenAfrica consortium, has uncovered new genetic risk factors for estimated glomerular filtration rate (eGFR)—a critical clinical measure of kidney function calculated from blood creatinine levels, age, sex, and body size, reflecting how well kidneys filter waste from the blood.

Prof. Michele Ramsay, Director of the Sydney Brenner Institute for Molecular Bioscience at Wits, emphasized the study's significance: “Our study demonstrates the importance of widening diversity in genomic datasets. Studying the rich genetic diversity found in African populations opens the door to discovering variants and biological pathways that may not be visible elsewhere, strengthening genomic science for everyone.” The research highlights Wits University's pivotal role in advancing precision medicine tailored to African genetic diversity.

Chronic Kidney Disease: A Major Burden in South Africa and Africa

Chronic kidney disease (CKD), characterized by a gradual loss of kidney function over time, affects an estimated 850 million people worldwide and ranks as the third fastest-growing cause of death globally. In South Africa, prevalence rates range from 6% to 17% among adults, with sub-Saharan Africa showing even higher figures around 10.7–18%. Factors like hypertension, diabetes, HIV, and limited access to dialysis or transplants exacerbate the issue, leading to disproportionately high rates of disability and mortality in African populations compared to global averages.

In South Africa, where public health systems strain under high disease burdens, CKD contributes significantly to healthcare costs and lost productivity. The condition often progresses silently until advanced stages, underscoring the need for early detection tools like genetic screening. Wits researchers, including nephrologist Dr. June Fabian, have long advocated for region-specific data to address these gaps, drawing from cohorts like the African Research Kidney (ARK) study in rural Mpumalanga.

Forming the KidneyGenAfrica Consortium: Pan-African Collaboration

KidneyGenAfrica, launched in 2025, unites African-led teams from Malawi, Uganda, Nigeria, South Africa, and global partners including the US, Europe, and beyond. Key cohorts include the Africa Wits-INDEPTH Partnership for Genomic Studies (AWI-GEN), led by Prof. Ramsay, spanning South Africa (4,527 participants), Ghana (3,475), Kenya (1,704), Burkina Faso, Nigeria, and Uganda (6,407); the ARK cohort (1,060 from South Africa); and Malawi's MEIRU (6,380). This consortium expands on prior efforts like H3Africa, ensuring ethical data sharing and capacity building in African genomics.

Queen Mary University of London's Prof. Segun Fatumo, co-lead, noted: “By combining data from across Eastern, Western, and Southern Africa... we have been able to uncover genetic insights that would have been impossible to detect otherwise.” Such partnerships exemplify how South African universities like Wits foster international research excellence.

Unpacking the Methodology: A Three-Stage Genome-Wide Association Study

The study employed a rigorous three-stage genome-wide association study (GWAS)—a method scanning millions of genetic variants across the genome to identify those statistically linked to traits like eGFR. Stage one involved regional discovery in Eastern (~10,481), Western (~6,604), and Southern Africa (~11,967) cohorts. Meta-analysis followed for continental (29,052) and pan-African (109,717, including diaspora like Million Veteran Program) levels.

• Discovery: Identified signals passing genome-wide significance (p < 5×10^-8).
• Replication: Tested in independent African cohorts.
• Fine-mapping: Pinpointed causal variants using statistical models.

Polygenic risk scores (PRS) were constructed and validated, showing superior performance when derived from genetically proximate populations (e.g., Southern African PRS in MEIRU: R²=0.11%). This step-by-step approach ensured robustness amid Africa's vast genetic diversity.

Key Genetic Discoveries: Novel Loci Unique to African Populations

The continental African meta-analysis pinpointed four independent loci associated with eGFR, two novel: rs4243063 near LOC645752 and rs73788952 in OPRM1 (opioid receptor mu 1 gene). Pan-African analysis yielded 19 loci, including three new ones: rs141647693 near ARG1 (arginine 1), rs12595073 near SORD2P, and rs1918516 near SQRDL.

These variants, common in Africans but rare or absent in Europeans/Asians, suggest population-specific pathways. Phenome-wide scans revealed pleiotropic effects on cardiometabolic (e.g., lipids, blood pressure) and immunological traits, opening avenues for multi-disease interventions.

APOL1 Variants: Divergent Risks Across African Contexts

APOL1 (apolipoprotein L1) high-risk alleles (G1/G2) dramatically elevate kidney failure risk in African Americans (threefold), driven by evolutionary pressures like trypanosome resistance. Surprisingly, in continental Africa, these variants occur at lower frequencies (high-risk genotypes 2.2-7.4% vs. higher in diaspora) with attenuated effects—significant only in Eastern Africa under recessive models (OR=4.38).

This divergence cautions against extrapolating diaspora models to Africa, highlighting evolutionary and environmental interactions unique to the continent.

Polygenic Risk Scores: Paving the Way for Precision Medicine

PRS aggregate effects of many variants to predict disease risk. Here, ancestry-matched PRS outperformed European-derived ones, with Southern African scores best predicting eGFR in Malawi's MEIRU cohort. This validates the need for African reference panels, enabling personalized screening and early interventions in high-risk communities.

In South Africa, where HIV and hypertension fuel CKD, such tools could transform nephrology at Wits-affiliated clinics.

Implications for Healthcare and Research in South Africa

The findings promise better CKD risk stratification, drug target identification (e.g., OPRM1 links to opioid pathways), and equitable genomics. For Wits, it bolsters its status as a genomics hub, training PhD students in bioinformatics and fostering spin-offs. Read the full Nature Communications paper for detailed analyses.

Dr. Jean-Tristan Brandenburg from Wits noted the study's role in ensuring African data sovereignty.

Wits University's Genomics Legacy and Capacity Building

Wits, through the Sydney Brenner Institute and AWI-GEN, has sequenced over 1,000 new African genomes recently, complementing this GWAS. Programs train young scientists, addressing SA's researcher shortages. Collaborations with QMUL exemplify global-south leadership.

Future Horizons: From Discovery to Clinical Application

KidneyGenAfrica plans expanded cohorts, functional studies on novel loci, and PRS integration into SA health systems. For higher education, it signals rising investment in African genomics, with Wits poised to lead. Explore Wits' press release for more.

This breakthrough not only illuminates kidney genetics but inspires the next generation of South African researchers.

Photo by Robiul Islam on Unsplash